Medical Education in Bladder Cancer
Medical Education in Bladder Cancer
At Johnson & Johnson, our vision is to find a solution for every patient across the spectrum of bladder cancer. Through collaboration with patients, caregivers, and leading experts in bladder cancer, we strive to transform the treatment landscape by harnessing the power of precision medicine and personalised management through early testing, novel intravesical drug delivery systems, and targeted therapies. With over 30 years of innovation in oncology, we are driven to get ahead of bladder cancer and deliver the best outcomes to patients, partners, and the oncology community.
Featured Bladder Cancer Events
Join our upcoming symposia and webinars hosted by our leading specialists. Register for events and access to post event recordings and materials available exclusively for J&J Medical Cloud users.
13-16 March 2026
EAU 2026
London, United Kingdom
Join us in these events in 2026. We look forward to sharing insights and engaging in meaningful medical education - details to come for each event.
12-16 September 2026
ECP 2026
Stockholm, Sweden
Join us in these events in 2026. We look forward to sharing insights and engaging in meaningful medical education - details to come for each event.
23-27 October 2026
ESMO 2026
Madrid, Spain
Join us in these events in 2026. We look forward to sharing insights and engaging in meaningful medical education - details to come for each event.
5-8 November 2026
EMUC 2026
Brussels, Belgium
Join us in these events in 2026. We look forward to sharing insights and engaging in meaningful medical education - details to come for each event.
Register or sign in for J&J Medical Cloud to unlock access to upcoming events, stay updated on the latest educational opportunities, and connect with a network of healthcare professionals.
Recently Added
Explore the latest educational content on our website, featuring expert-led sessions, insights from KOLs, and practical tools designed to support your continuous learning and enhance your clinical practice.
ECP 2025
An expert panel - Prof. Glen Kristiansen, Dr. Alessia Cimadamore, Dr. Dora Niedersüβ-Beke and Dr. Beatriz Bellosillo discuss progress in early genetic testing, personalised care and multidisciplinary approaches in uropathology.
ESMO 2025
An expert panel – including Prof. Enrique Grande, Prof. Syed Hussain, and Dr. Patrizia Giannatempo – examine key clinical considerations in GU cancer care.
EMUC 2025
A panel of expert speakers at our bladder cancer industry symposium explored the latest treatment strategies in BCG-unresponsive HR-NMIBC.
Introducing J&J withMe
A patient-centric platform designed to support patients throughout their healthcare journey. It provides personalised, high-quality content and services to enhance patient engagement.
By empowering informed, proactive patients, J&J withMe helps improve treatment outcomes.
Learn how this platform can strengthen your patient relationships — explore J&J withMe today!
Expert Insights from Key Opinion Leaders at ESMO 2025
Gain valuable insights from leading experts in the field as they share their knowledge on key topics and provide informed answers to common questions. Stay informed and enhance your understanding with expert perspectives!
How is precision medicine transforming the treatment landscape of mUC management?
How is precision medicine transforming the treatment landscape of mUC management?
Recent clinical advances in mUC treatment, and how to personalise therapy and treatment sequencing for best patient outcomes – filmed at ESMO 2025.
Prof. Enrique Grande, Prof Syed Hussain, Dr. Patrizia Giannatempo and Dr Félix Guerrero-Ramos discuss the latest in precision medicine in bladder cancer.
Prof. Grande discusses unmet needs, guideline integration and tailoring treatment strategies
Prof. Grande discusses unmet needs, guideline integration and tailoring treatment strategies
What are the new treatment options and management strategies for patients with mUC? Click here to listen to the experts discussing the factors impacting treatment choices, patient selection and personalised management strategies
Prof. Syed Hussain discusses treatment at second line and optimising patient outcomes
Prof. Syed Hussain discusses treatment at second line and optimising patient outcomes
What are the new treatment options and management strategies for patients with mUC? Click here to listen to the experts discussing the factors impacting treatment choices, patient selection and personalised management strategies
Dr. Patrizia Giannatempo discusses AE management and therapy personalisation for mUC patients
Dr. Patrizia Giannatempo discusses AE management and therapy personalisation for mUC patients
What are the new treatment options and management strategies for patients with mUC? Click here to listen to the experts discussing the factors impacting treatment choices, patient selection and personalised management strategies
Expert Insights from Key Opinion Leaders at EMUC 2025
Dr. Marco Moschini shares his views on current guidelines regarding risk stratification and BCG response categories
Dr. Marco Moschini shares his views on current guidelines regarding risk stratification and BCG response categories
How are the novel targeted therapies and drug delivery methods transforming the treatment landscape for HR-NMIBC after BCG-treatment? Click here to listen to the experts discussing the exciting new findings in HR-NMIBC, and their advice and tips on management and follow-up.
Dr. Laura Mertens shares her views on unmet needs and tips and advice for managing patients with HR-NMIBC post BCG
Dr. Laura Mertens shares her views on unmet needs and tips and advice for managing patients with HR-NMIBC post BCG
How are the novel targeted therapies and drug delivery methods transforming the treatment landscape for HR-NMIBC after BCG-treatment? Click here to listen to the experts discussing the exciting new findings in HR-NMIBC, and their advice and tips on management and follow-up.
Prof. Evanguelos Xylinas provides an overview of the current treatment landscape in HR-NMIBC and the future outlook with novel therapies
Prof. Evanguelos Xylinas provides an overview of the current treatment landscape in HR-NMIBC and the future outlook with novel therapies
How are the novel targeted therapies and drug delivery methods transforming the treatment landscape for HR-NMIBC after BCG-treatment? Click here to listen to the experts discussing the exciting new findings in HR-NMIBC, and their advice and tips on management and follow-up.
Note: To access more expert insights, you can register or sign in to J&J Medical Cloud. Stay informed about the latest educational resources and updates from Johnson & Johnson Innovative Medicine by signing up for our communications.
Our Commitment
Therapeutic Areas
Our scientists and researchers are pioneering the path from lab to life and championing patients each step of the way.
Expert-Driven Education
Our educational programs are developed and reviewed in partnership with a global network of healthcare leaders.
Support‑ Focused
We work with medical societies to support joint initiatives that enhance healthcare outcomes and foster professional education.
Connecting Scientific Expertise
Supporting healthcare professionals to engage in ongoing discussions about the latest scientific advancements.
Our Responsibility to Medical Education
Stay in Touch
We value your connection. Sign up to stay informed about the latest educational resources, and updates. By subscribing, you'll receive timely notifications and exclusive content tailored to your interests.
Contact us
To report an Adverse Event (medication side effect) or a Product Quality Complaint (an issue with one of our products), please select the appropriate link from the Contact dropdown menu. To submit a medical information request, choose the Medical Information page.
CP-556801 - January 2026
Janssen Pharmaceutica NV